Saudi Arabia Vaccines Market Size & Outlook, 2025-2033
Saudi Arabia Vaccines Market Insights
- According to Reed Intelligence analysis, the Saudi Arabia Vaccines Market size was USD 852.52 Million in 2024 and is projected to reach USD 1522.63 Million by 2033.
- The Saudi Arabia market is projected to grow at a CAGR of 6.63% between 2025 and 2033.
- By segment, Monovalent emerged as the largest By Type in terms of market size in 2024.
- Monovalent is anticipated to remain the most attractive By Type segment, recording the fastest growth during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2024, Saudi Arabia held 1.26% of the global Vaccines Market size.
- By 2033, United States is anticipated to capture the largest share of the global Vaccines Market.
- In Middle East and Africa, United Arab Emirates is expected to lead the regional Vaccines Market size by 2033.
- Turkey will remain the fastest-growing market in Middle East and Africa, reaching USD 625.63 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 852.52 Million |
| Market Size In 2033 | USD 1522.63 Million |
| Largest segment | Monovalent |
| Units | Revenue in USD Million |
| CAGR | 6.63% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Route of Administration |
|
| By Disease Indication |
|
| By Age Group |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Saudi Arabia Vaccines Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monovalent | XX.x | XX.x | XX.x | 538.11 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Multivalent | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Saudi Arabia Vaccines Market By Route of Administration 2025-2033 (USD Million)
| By Route of Administration | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | XX.x | XX.x | XX.x | 386.02 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Parenteral | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nasal | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Saudi Arabia Vaccines Market By Disease Indication 2025-2033 (USD Million)
| By Disease Indication | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viral | XX.x | XX.x | XX.x | 553.8 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Bacterial | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Saudi Arabia Vaccines Market By Age Group 2025-2033 (USD Million)
| By Age Group | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pediatric | XX.x | XX.x | XX.x | 528.9 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Adult | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
